Tumour regression after endostatin therapy

William R. Black and R. Christopher Agner
Additional contact information
William R. Black: Departments of Internal Medicine and Medical Oncology,Rowan Regional Medical Center
R. Christopher Agner: Departments of Internal Medicine and Medical Oncology,Rowan Regional Medical Center

Nature, 1998, vol. 391, issue 6666, 450-450

Abstract: Abstract It was with great interest that we read the report1 on the lack of acquired drug resistance to repeated doses of endostatin in experimental cancers in mice. Of particular interest is the unprecedented finding that each tumour type became indefinitely dormant after a varying number of treatment cycles. We believe one explanation for this phenomenon might be found in the clinical observation that, after complete regression of large bulky tumours, rebiopsy of the primary tumour site will frequently show large amounts of fibrosis or scarring.

Date: 1998
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/35064 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:391:y:1998:i:6666:d:10.1038_35064

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/35064

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().